Opko Health (OPK) Current Deferred Revenue (2014 - 2024)
Opko Health (OPK) reported Current Deferred Revenue of $6000.0 for Q4 2024, down 14.29% on a YoY basis from $7000.0 in Q1 2024, and down 14.29% quarter-over-quarter from $7000.0 in Q4 2023.
Opko Health (OPK) Current Deferred Revenue (2014 - 2024) Analysis & Trends
Opko Health has reported Current Deferred Revenue for 4 years, with the latest figure at $6000.0 in Q4 2024.
- For the quarter ending Q4 2024, Current Deferred Revenue fell 14.29% year-over-year to $6000.0; the trailing twelve-month figure through Dec 2024 stood at $6000.0 (down 14.29% YoY), and the FY2024 full-year result was $6000.0, down 14.29% from the prior year.
- Current Deferred Revenue for Q4 2024 stood at $6000.0, down from $7000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $7000.0 in Q4 2023, with the low at $6000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn |
| 10 | Opko Health | 1.09 Bn | 747.11 Mn | 45.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2015 | 254.10 Mn |
| Dec 31, 2014 | 6.70 Mn |